CP-673451: Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 is a potent, ATP-competitive inhibitor targeting PDGFRα and PDGFRβ, displaying IC50 values of 10 nM and 1 nM, respectively, with >180-fold selectivity over c-Kit and negligible activity on VEGFR or EGFR (see CP-673451 product page). In vivo, oral dosing at 50 mg/kg reduces PDGFRβ phosphorylation by >50% for four hours (rat C6 xenograft model) and suppresses PDGF-BB-induced angiogenesis by 70–90% (mouse sponge assay) [Pladevall-Morera et al., 2022, DOI]. CP-673451 inhibits tumor growth and microvessel density in multiple xenograft models, including ATRX-deficient gliomas. The compound is insoluble in water but dissolves in DMSO (≥20.9 mg/mL) and ethanol (≥2.39 mg/mL with warming/sonication). It is widely used for functional dissection of PDGFR signaling, angiogenesis inhibition, and tumor suppression in preclinical cancer research.

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases (RTKs) that mediate critical signaling pathways for cell proliferation, migration, and angiogenesis. Aberrant PDGFR signaling is implicated in tumorigenesis, particularly in high-grade gliomas and other cancers exhibiting PDGFR amplification or mutations [Pladevall-Morera et al., 2022, DOI]. ATRX-deficient glioma cells show genetic instability and are particularly sensitive to PDGFR inhibitors, suggesting a synthetic vulnerability exploitable for therapy. Selective inhibition of PDGFR signaling enables precise investigation of angiogenic mechanisms and tumor–stroma interactions. CP-673451’s selectivity profile allows for confident attribution of phenotypes to PDGFR blockade, minimizing confounding effects from off-target kinase inhibition. This compound is integral to workflows dissecting the molecular basis of cancer progression and resistance in PDGFR-driven models.

Mechanism of Action of CP-673451

CP-673451 acts as an ATP-competitive inhibitor, binding to the kinase domains of PDGFRα and PDGFRβ. It blocks receptor autophosphorylation and downstream signaling cascades, including PI3K/AKT and MAPK pathways. The compound demonstrates nanomolar potency: IC50 = 10 nM (PDGFRα) and IC50 = 1 nM (PDGFRβ) in biochemical assays. In PAE-β cellular models, the IC50 for PDGFRβ inhibition is 6.4 nM. Selectivity is a key feature: CP-673451 displays over 180-fold selectivity versus c-Kit (IC50 = 1.1 μM in H526 cells) and negligible inhibition of VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR at relevant concentrations (ApexBio). By targeting PDGFR-driven signaling, CP-673451 inhibits mitogenic, survival, and angiogenic pathways essential for tumor maintenance and neovascularization.

Evidence & Benchmarks

• CP-673451 inhibits PDGFRβ autophosphorylation in vitro with an IC50 of 1 nM in biochemical assays (ApexBio).
• In PAE-β cellular assays, CP-673451 achieves an IC50 of 6.4 nM for PDGFRβ inhibition (ApexBio).
• It displays >180-fold selectivity for PDGFRβ over c-Kit in H526 cells (IC50 for c-Kit = 1.1 μM) (ApexBio).
• Oral administration at 50 mg/kg in rat C6 glioblastoma xenograft models reduces PDGFRβ phosphorylation by >50% for 4 hours (Pladevall-Morera et al., 2022, DOI).
• In a mouse sponge angiogenesis model, CP-673451 inhibits PDGF-BB-induced angiogenesis by 70–90% (DOI).
• CP-673451 suppresses tumor growth and decreases microvessel density in xenograft models including Colo205, LS174T, H460, and U87MG (DOI).
• ATRX-deficient high-grade glioma cells exhibit increased sensitivity to PDGFR inhibitors, including CP-673451 (Pladevall-Morera et al., 2022, DOI).

This article extends the mechanistic and benchmarking discussion found in "CP-673451 and the Future of Selective PDGFR Inhibition" by adding up-to-date, quantitative efficacy data and clarifying selectivity in ATRX-deficient glioma models. For further context, "CP-673451: Transforming Glioma Research" discusses strategic perspectives; this article provides granular protocol and selectivity details to support experimental reproducibility.

Applications, Limits & Misconceptions

CP-673451 is widely used in cancer research for:

• Dissecting PDGFR signaling pathway components in vitro and in vivo
• Evaluating angiogenesis inhibition in PDGF-driven models
• Assessing tumor growth suppression in xenograft models, including ATRX-deficient gliomas
• Benchmarking selectivity against other kinase inhibitors in translational studies

Common Pitfalls or Misconceptions

• Off-target inhibition: Despite high selectivity, CP-673451 moderately inhibits c-Kit at micromolar concentrations; effects observed above 1 μM may not be PDGFR-specific.
• Solubility constraints: The compound is insoluble in water; improper dissolution can lead to precipitation and loss of activity. Use DMSO or ethanol with warming and sonication.
• In vivo dosing limits: Doses above 50 mg/kg (oral) may not increase efficacy and raise toxicity risks; always titrate for specific models.
• Short-term solution stability: CP-673451 solutions are stable for short-term use only. Stock solutions in DMSO should be stored at -20°C for up to several months.
• Not a clinical drug: CP-673451 is not approved for therapeutic use in humans; it is intended strictly for research applications.

Workflow Integration & Parameters

For in vitro studies, CP-673451 is typically dissolved in DMSO at concentrations ≥20.9 mg/mL. Ethanol can be used at ≥2.39 mg/mL with warming and ultrasonic treatment. For cell-based assays, working concentrations range from 1 nM to 1 μM, depending on the model and endpoint. In vivo, oral dosing at 50 mg/kg is standard in rat xenograft protocols, with observable effects on PDGFRβ phosphorylation and angiogenesis within 4 hours post-administration [Pladevall-Morera et al., 2022, DOI]. For storage, retain the solid at -20°C. Stock solutions in DMSO can be kept below -20°C for several months; avoid repeated freeze-thaw cycles. Use freshly prepared working solutions for optimal reproducibility.

Conclusion & Outlook

CP-673451 remains a reference-standard tool for studying PDGFR signaling, angiogenesis, and tumorigenesis in preclinical cancer models. Its nanomolar potency and high selectivity enable precise functional dissection, especially in genetically defined backgrounds such as ATRX-deficient gliomas (Pladevall-Morera et al., 2022). As new data emerge, incorporating molecular stratification (e.g., ATRX status) will sharpen the translational value of PDGFR inhibition studies. For comprehensive product information and ordering, consult the CP-673451 product page.